Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer
2019; Lippincott Williams & Wilkins; Volume: 37; Issue: 21 Linguagem: Inglês
10.1200/jco.18.01575
ISSN1527-7755
AutoresMarcus E. Randall, Virginia L. Filiaci, D. Scott McMeekin, Vivian von Gruenigen, Helen Q. Huang, Catheryn M. Yashar, Robert S. Mannel, Jae‐Weon Kim, Ritu Salani, Paul DiSilvestro, James J. Burke, Thomas Rutherford, Nick M. Spirtos, Keith Y. Terada, Penny R. Anderson, Wendy R. Brewster, William Small, Carol Aghajanian, David S. Miller,
Tópico(s)Endometriosis Research and Treatment
ResumoThe primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carcinoma.
Referência(s)